We’re excited to announce that on Tuesday, April 24, 2018, the U.S. Food and Drug Administration (FDA) granted approval of JYNARQUE™ (pronounced jin-AR-kew and also known as tolvaptan) to be the first treatment in the United States for adult patients with autosomal dominant polycystic kidney disease (ADPKD), the most common...
We are hosting a FREE PKD Patient Forum in Quebec City! If you, your family or loved ones live in the area, join us and members of the local PKD community to learn more about PKD and what resources are available...
Kidney Month is recognized in March across Canada and the United States. We spend this time raising awareness of the importance of our kidneys to our overall health, and to reduce the frequency and impact kidney disease and its associated health problems have on an international level. We encourage you...
Submitted by Chiara Gamberi, Ph. D. Affiliate Assistant Professor, Department of Biology, Concordia University
Season's greetings to you and yours from the PKD Foundation of Canada!
We are pleased to share some encouraging news regarding the treatment landscape for those living with ADPKD. Today, Otsuka announced results from their Phase 3 REPRISE trial of tolvaptan in patients with autosomal dominant polycystic kidney disease (ADPKD). This data was presented at the American Society of Nephrology (ASN) Conference...
Since 2007, the PKD Foundation of Canada has raised over $1M for critical PKD research, education, advocacy and awareness through our Walk to END PKD campaign! Truly an amazing feat for our grassroots organization.
Registration is open for the 2017 Walk to END PKD, the PKD Foundation of Canada's signature fundraising campaign.
We are thrilled to introduce the new name and new look for our signature fundraising event! The new name, Walk to END PKD (formerly Walk for PKD), better aligns with our mission to discover treatments and a cure for polycystic kidney disease and improve the lives of all it affects....
We are glad to share some great news for the Canadian PKD community, as tolvaptan receives positive results from an additional one year international trial. The trial outcome was positive for tolvaptan in the treatment of ADPKD. Also of note, the trial had participation from Canadian patients and nephrologists.